Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders with a comprehensive overview of the company’s 2024 milestones and strategic initiatives for 2025. The full webcast is available here: https://youtu.be/NA3kCUZZIpI. During the webcast, Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, detailed significant progress in the company’s pivotal Phase 3 studies for Buntanetap, its lead drug candidate targeting neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. These studies aim to demonstrate both symptomatic relief and disease-modifying effects, aligning with Annovis Bio’s mission to address the substantial unmet needs of patients and caregivers.
“2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” stated Dr. Maccecchini. “Our Phase 3 programs are designed to advance our understanding of neurodegeneration and bring us closer to delivering meaningful treatments that improve patients’ lives.”
The webcast also highlighted financial developments, including the recent securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth.
Webcast Highlights Include:
- Progress on pivotal Phase 3 Alzheimer’s and Parkinson’s clinical programs.
- Financial updates and future fundraising plans to support key initiatives.
- Insights into the company’s innovative approach targeting multiple neurotoxic proteins.
- Strategic plans for 2025 to drive regulatory and clinical milestones.
The event underscores Annovis Bio’s commitment to transparency and open communication with its investors as it continues to advance its mission to combat neurodegenerative diseases through innovative therapies.
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
